Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Aligos Therapeutics, Inc. - Common stock
(NQ:
ALGS
)
6.680
-0.980 (-12.79%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aligos Therapeutics, Inc. - Common stock
< Previous
1
2
3
4
5
6
7
8
Next >
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184
October 22, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024
October 15, 2024
Three abstracts accepted for poster presentations on ALG-000184 and ALG-055009
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 11, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Recap: Aligos Therapeutics Q4 Earnings
↗
March 12, 2024
Via
Benzinga
Aligos Therapeutics Appoints David Perry as Vice President of Business Development
October 01, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Present at Investor Conferences in October
September 30, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
September 24, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
September 19, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
September 18, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 13, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces Reverse Stock Split
August 15, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Strengthens Board with Two New Independent Directors
August 08, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results
August 06, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024
July 30, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
↗
July 27, 2024
Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus...
Via
Talk Markets
Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.
July 22, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB
July 10, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
June 05, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
May 22, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
May 21, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
ALGS Stock Earnings: Aligos Therapeutics Misses EPS for Q1 2024
↗
May 07, 2024
ALGS stock results show that Aligos Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
May 07, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
April 30, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
April 25, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
April 25, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
April 09, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
April 03, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
March 27, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
March 18, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
↗
March 15, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
